Last reviewed · How we verify
Botulinum toxin A
Botulinum toxin A is a Neurotoxin; Acetylcholine release inhibitor Biologic drug developed by University of Calgary. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Strabismus. Also known as: Botox, Botox, Botulinum toxin A, OnabotulinumtoxinA, BTX-A.
Botulinum toxin A blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin A blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | Botulinum toxin A |
|---|---|
| Also known as | Botox, Botox, Botulinum toxin A, OnabotulinumtoxinA, BTX-A, BoNT A |
| Sponsor | University of Calgary |
| Drug class | Neurotoxin; Acetylcholine release inhibitor |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Biologic |
| Therapeutic area | Neurology; Dermatology; Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin A is a neurotoxin that irreversibly cleaves SNARE proteins (specifically SNAP-25) required for acetylcholine vesicle release at the presynaptic terminal. This prevents neuromuscular transmission and results in flaccid paralysis of the targeted muscle. The effect is temporary, lasting 3-4 months, after which new nerve terminals form and muscle function gradually returns.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Hyperhidrosis
- Spasticity
- Cosmetic wrinkle reduction
Common side effects
- Headache
- Neck pain
- Muscle weakness
- Injection site pain
- Flu-like symptoms
- Eyelid ptosis
- Diplopia
Key clinical trials
- DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia (PHASE1, PHASE2)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Botulinum Toxin for the Treatment of Involuntary Movement Disorders
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- Evaluation of Spasticity, Neuropathic Pain, and Gait Analysis in Stroke Patients Receiving Tolperison Therapy After Botulinum Toxin Injection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum toxin A CI brief — competitive landscape report
- Botulinum toxin A updates RSS · CI watch RSS
- University of Calgary portfolio CI
Frequently asked questions about Botulinum toxin A
What is Botulinum toxin A?
How does Botulinum toxin A work?
What is Botulinum toxin A used for?
Who makes Botulinum toxin A?
Is Botulinum toxin A also known as anything else?
What drug class is Botulinum toxin A in?
What development phase is Botulinum toxin A in?
What are the side effects of Botulinum toxin A?
What does Botulinum toxin A target?
Related
- Drug class: All Neurotoxin; Acetylcholine release inhibitor drugs
- Target: All drugs targeting SNAP-25 (synaptosome-associated protein of 25 kDa)
- Manufacturer: University of Calgary — full pipeline
- Therapeutic area: All drugs in Neurology; Dermatology; Aesthetics
- Indication: Drugs for Cervical dystonia
- Indication: Drugs for Blepharospasm
- Indication: Drugs for Strabismus
- Also known as: Botox, Botox, Botulinum toxin A, OnabotulinumtoxinA, BTX-A, BoNT A
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing